Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Recurrence × nintedanib × Clear all

Phase

Status

Completed 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Recurrence 1 Neoplasm Metastasis 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma of Lung 1

Interventions

Dexamethasone 14 Rituximab 6 venetoclax 4 Lenalidomide 4 Cytarabine 4 Bortezomib 4 Bendamustine Hydrochloride 4 selinexor 3 pomalidomide 3 pembrolizumab 3 ibrutinib 3 carfilzomib 3 Paclitaxel 3 Gemcitabine 3 Drug Therapy 3 Cyclophosphamide 3 Calcium Dobesilate 3 ixazomib 2 gilteritinib 2 fludarabine phosphate 2 fludarabine 2 elotuzumab 2 daratumumab 2 belinostat 2 Tablets 2 Surveys and Questionnaires 2 Panobinostat 2 Oxaliplatin 2 Etoposide 2 Cetuximab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03361319 2020-11-24

N3

Royal Marsden NHS Foundation Trust

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡